Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the United States. Its launch comes years after that of Pfizer’s Jak inhibitor, Xeljanz (…
Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the United States. Its launch comes years after that of Pfizer’s Jak inhibitor, Xeljanz (…
Dupixent (Sanofi/Regeneron), a first-in-class biologic that inhibits IL-4/IL-13 signaling, was approved for the treatment of eosinophilic asthma and oral-corticosteroid-dependent asthma in October…
Dupixent (Sanofi/Regeneron), a first-in-class biologic that inhibits IL-4/IL-13 signaling, was approved for the treatment of eosinophilic asthma and oral-corticosteroid-dependent asthma in October…
Market Outlook Pfizer’s Xeljanz is the first-in-class Jak inhibitor approved for ulcerative colitis (UC) in the United States and the first targeted oral therapy to launch for moderate to severe…
The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy has been the standard of care for ovarian cancer; however, treatment is changing to a targeted approach with…
Market Outlook Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s…
Market Outlook Therapeutic options for gastroesophageal cancer are limited; only two targeted agents are approved to treat gastric and GEJ adenocarcinoma in the major pharmaceutical markets…
Market Outlook Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the main treatment for prostate cancer and are routinely used throughout the course…
Market Outlook: Squamous cell carcinoma of the head and neck (SCCHN) is an anatomically and biologically heterogeneous disease that has historically proven to be a complex challenge for drug…
SLE is an autoimmune condition characterized by varied symptoms and multiple organ involvement, making it a complex disease that is difficult to manage. Moreover, challenges in clinical trial…
Colorectal cancer is the third-most-common cancer globally and is associated with a five-year overall survival of 65.1%. Current treatment for metastatic colorectal cancer is dominated by…
Muscular dystrophies (MDs) are a spectrum of genetic disorders characterized by muscle weakness that, in severe disease forms, can lead to loss of ambulation and early death. Duchenne muscular…
Market Outlook As one of the larger segments in the overall market for acute pain therapies, the treatment of postoperative pain has experienced substantial growth over the past decade due to the…
Market Outlook Pfizer’s Xeljanz is the fist-in-class Jak inhibitor approved for ulcerative colitis (UC) in the United States, and the first targeted oral therapy to launch for the moderate to…